Mediar Therapeutics

Mediar Therapeutics Inc. (Cambridge, MA, USA) was founded on pioneering fibrosis research from Mass General and Brigham & Women’s Hospitals in partnership with Mass General Brigham Ventures in 2018 with the goal to transform the treatment of fibrotic disease by targeting a key driver of disease progression, a recently discovered cell type called the Myofibroblast.
 
Mediar, advancing a portfolio of first-in-class therapies that halt and even reverse the course of fibrosis, raised a $105M financing in 2022, including an $85 million Series A financing co-led by Novartis Venture Fund and Sofinnova Partners and with participation from Gimv, Pfizer Ventures, Mission BioCapital, Pureos, Bristol-Myers Squibb, Eli Lilly, Ono Venture Investment, and Mass General Brigham Ventures.